A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

Inclusion Criteria:

• Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
• Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion Criteria:

• Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
• Others who are assessed to be ineligible for the study by the investigator or subinvestigator.